Investor Presentation

140 Investor presentation First six months of 2022 Solid operating profit growth driven by Diabetes care Operating profit Operating profit split by franchise DKK billion Percent of sales 1% -4% 11% 3% 8% 70 60% 5% 3% 6% 7% 13% 16% 60 22% 60 50% 50 40 40 30 30 20 20 10 0 2017 CER: Constant exchange rates 2018 Operating profit Operating profit as % of sales 40% Novo NordiskⓇ 30% 84% 78% 20% 10% 0% 2019 2020 2021 2017 Reported operating profit growth Operating profit growth at CER 2021 Diabetes and Obesity care Rare disease

View entire presentation